By potentially altering the ability to metabolize and excrete carcinogens and chemotherapeutic drugs, UGT1A1 polymorphisms can influence both cancer risk and clinical outcomes in different cancer types [39,40]. The gene discussed is UGT1A1; the disease is cancer.